Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
ConclusionsIn the KATHERINE study, T-DM1 demonstrated increased efficacy compared to trastuzumab in Chinese patients. Consistent with previous data in Asian patients, T-DM1 was associated with more grade  ≥ 3 AEs, and AEs leading to discontinuation, which was driven by an increase in thrombocytopenia. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 15, 2021 Category: Cancer & Oncology Source Type: research

Prosigna test in breast cancer: real-life experience
ConclusionWe present one of the largest cohorts of HR  + , HER2- BC patients at intermediate risk of recurrence, in whom a Prosigna test was used to guide the adjuvant therapy decision in a real-life setting, resulting in a 44% decrease in the indication for chemotherapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 15, 2021 Category: Cancer & Oncology Source Type: research

ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
AbstractIntroductionNeoadjuvant endocrine therapy is often utilized to downstage Estrogen Receptor-positive (ER+) breast cancer prior to surgery. However, this approach is sometimes met with endocrine resistance mechanisms within the tumor. This trial examines the safety and efficacy of tamoxifen in combination with an mTORC1/2 inhibitor, TAK-228, in the neoadjuvant treatment of ER+ breast cancer.MethodsIn this single-arm, open-label trial, pre- and post-menopausal women were enrolled to receive neoadjuvant tamoxifen (20  mg daily) with TAK-228 (30 mg weekly) for 16 weeks prior to surgery. Patient had tissue...
Source: Breast Cancer Research and Treatment - April 15, 2021 Category: Cancer & Oncology Source Type: research

Gail model utilization in predicting breast cancer risk in Egyptian women: a cross-sectional study
ConclusionWe revealed that modified Gail model had a well-fitting and discrimination accuracy in Egyptian women when compared with other countries. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 14, 2021 Category: Cancer & Oncology Source Type: research

Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
ConclusionThe addition of cituxumumab to lapatinib and capecitabine did not improve PFS or OS compared with lapatinib and capecitabine in patients with HER2-positive MBC.Clinical trial registryClinicalTrials.gov Identifier: NCT00684983 (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 14, 2021 Category: Cancer & Oncology Source Type: research

Pre-diagnosis major life stressors and breast cancer outcomes
ConclusionsPsychological distress is prevalent prior to breast cancer diagnosis and may merit early intervention. While additional study in diverse populations is needed, current data suggest possible associations between pre-diagnosis psychological distress and surgical decision making, specifically mastectomy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 12, 2021 Category: Cancer & Oncology Source Type: research

SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast
ConclusionsOur findings may suggest a potential involvement of epigenetic regulation viaSETD2 alterations and downstream H3K36me3 on PT development.SETD2 mutations may occur early in the pathogenic process of PTs and its loss per se may not be sufficient for progression to malignancy. Exclusive alterations ofSETD2 in PT can be used as markers for the diagnosis of fibroepithelial lesions. The association of H3K36me3 with SETD2 mutations may also indicate the value of evaluation of H3K36me3 expression in the diagnosis of fibroepithelial lesions. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 12, 2021 Category: Cancer & Oncology Source Type: research

Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis
This study aims to determine the true extent of axillary node disease in negative preoperative AUS patients.MethodsA 10-year breast cancer registry was reviewed to identify women with pathologically confirmed T1-2 invasive breast cancer and a negative preoperative AUS. Patients who received neoadjuvant chemotherapy were excluded. Combined positive lymph node count of SLNB  ± ALND was used to determine total nodal burden (TNB). Axillae were classified into low nodal burden (LNB) defined as 1–2 positive nodes and high nodal burden (HNB) defined as ≥ 3 positive nodes.Results762 pati...
Source: Breast Cancer Research and Treatment - April 10, 2021 Category: Cancer & Oncology Source Type: research

Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2 − metastatic breast cancer
ConclusionOur results indicate that dose reduction of ribociclib is safe and do not compromise the efficacy of the treatment. Furthermore, the study supports translation of results from the MONALEESA trials to patients treated in real-world clinical settings. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 10, 2021 Category: Cancer & Oncology Source Type: research

Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer
ConclusionOur results support the feasibility of combining propranolol (up to 80  mg ER) with neoadjuvant taxane/anthracycline-based chemotherapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 10, 2021 Category: Cancer & Oncology Source Type: research

Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland
ConclusionOver the 8  years of the study, a 62.5% reduction in CT use was achieved with savings of over €1,900,000. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 9, 2021 Category: Cancer & Oncology Source Type: research

Management and outcomes of men diagnosed with primary breast cancer
ConclusionsMale breast cancer remains a rare diagnosis. Despite this, the majority of patients in this study received standard of care therapy and experienced excellent oncologic outcomes. Penetration for genetic testing improved over time. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 8, 2021 Category: Cancer & Oncology Source Type: research

DUCHESS: an evaluation of the duc tal carcinoma in situ score for decisions on radiot he rapy in patients with low/intermediate-ri s k DCI S
AbstractBackgroundIdentification of women with DCIS who have a very low risk of local recurrence risk (LRR) after breast-conserving surgery (BCS) is needed to de-escalate therapy. We evaluated the impact of 10-year LRR estimates after BCS, calculated by the integration of a 12-gene molecular expression assay (Oncotype Breast DCIS Score®) and clinicopathological features (CPFs), on its ability to change radiation oncologists ’ recommendations for RT after BCS for DCIS.MethodsProspective cohort study of women with DCIS treated with BCS. Eligibility criteria were as follows: age  >  45 years, t...
Source: Breast Cancer Research and Treatment - April 8, 2021 Category: Cancer & Oncology Source Type: research

Multigene assessment of genetic risk for women for two or more breast cancers
ConclusionsThis study demonstrated that several high and moderate penetrance breast cancer susceptibility genes are associated with  ≥ 2 breast cancers, affirming the association of two or more breast cancers with diverse genetic etiologies. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 7, 2021 Category: Cancer & Oncology Source Type: research

Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer
ConclusionsCardiotoxicity was relatively common (16.6%), but symptomatic heart failure on trastuzumab was rare in our cohort. The HFA-ICOS score identifies patients at high risk of cardiotoxicity. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 5, 2021 Category: Cancer & Oncology Source Type: research

Breast cancer survivors: physical and mental quality of life 10 years following diagnosis, a case-control study
ConclusionHRQOL of BC survivors should gain more attention in the area of cancer care, especially when comorbidities are present. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 5, 2021 Category: Cancer & Oncology Source Type: research

Correction to: Mammography use and breast cancer incidence among older U.S. women
A correction to this paper has been published: https://doi.org/10.1007/s10549-021-06212-9 (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 5, 2021 Category: Cancer & Oncology Source Type: research

HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines
ConclusionsHER2 concordance was highest between Oncotype DX (99.6%) and FISH per 2018 guidelines. This suggests that the ASCO/CAP 2018 guidelines improved the accurate stratification of HER2-equivocal cases. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 3, 2021 Category: Cancer & Oncology Source Type: research

Cardioprotective medication use in Black and white breast cancer survivors
This study examined the prevalence of cardioprotective medication use in survivors and identified factors associated with use by race.MethodsThe analysis included women enrolled in the Women ’s Hormonal Initiation and Persistence study, a longitudinal observational trial of breast cancer survivors. The study outcome, angiotensin converting enzyme inhibitor (ACEi) or ß-Blocker (BB) use, were ascertained from pharmacy records. Demographic, psychosocial, healthcare, and quality of life factors were collected from surveys and clinical data were abstracted from medical records. Bivariate associations by race and ACE...
Source: Breast Cancer Research and Treatment - April 2, 2021 Category: Cancer & Oncology Source Type: research

Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer
AbstractBackgroundTreatment options for metastatic breast cancer (MBC) refractory to anthracyclines and taxanes are limited. In a phase III trial, eribulin demonstrated a significant improvement in overall survival compared to treatment of physician ’s choice, but had limited tolerability because of neutropenia and peripheral neuropathy. Based on prior studies of alternative treatment schedules with other therapies, we hypothesized that a low-dose metronomic schedule of eribulin would permit patients to remain on treatment more consistently w ithout treatment delays, resulting in longer time to progression, and impro...
Source: Breast Cancer Research and Treatment - April 2, 2021 Category: Cancer & Oncology Source Type: research

Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study
AbstractPurposeThere are conflicting results on the potential role of HER2-status on the efficacy of aromatase inhibitors (AIs) and tamoxifen (TAM) in patients with hormone receptor (HR)-positive breast cancer (BC). The purpose of this population-based cohort study was to investigate the potential benefit of AIs compared to TAM as adjuvant therapy in postmenopausal BC patients by HER2-status in the era of modern therapy with HER2-blockade.MethodsA population-based cohort study was performed including all postmenopausal women diagnosed with HR-positive BC without distant metastasis between 2007 and 2012 in three healthcare ...
Source: Breast Cancer Research and Treatment - April 1, 2021 Category: Cancer & Oncology Source Type: research

Tumor phenotype and concordance in synchronous bilateral breast cancer in young women
ConclusionsBilateral breast cancer is uncommon among young women diagnosed with breast cancer at age  ≤ 40. In our cohort, the majority of invasive tumors were of the luminal phenotype, though some differed by grade or HER2 status. These findings support the need for thorough pathologic workup of bilateral disease when it is found in young women with breast cancer to determine risk and tailor treatment. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 1, 2021 Category: Cancer & Oncology Source Type: research

Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset
ConclusionSite and fatality of de-novo mets vary by subtype and by race. This information may help improve risk stratification and post-diagnostic surveillance to ultimately reduce BC mortality. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 25, 2021 Category: Cancer & Oncology Source Type: research

Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer
ConclusionsHigh lymphocyte and monocyte counts are associated with lower recurrence rate in early-stage breast cancer, particularly in obese patients and those reporting alcohol consumption. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 25, 2021 Category: Cancer & Oncology Source Type: research

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
ConclusionQuestions around optimal use of adjuvant bisphosphonates in patients with EBC still exist. There is interest among physicians in performing trials of de-escalation of these agents. The results of this survey will assist in designing pragmatic clinical trials to address this question. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 23, 2021 Category: Cancer & Oncology Source Type: research

Interobserver concordance in visual assessment of Ki67 immunohistochemistry in surgical excision specimens from patients with lymph node-negative breast cancer
ConclusionsInterobserver and prognostic concordance in Ki67 immunohistochemistry assessments was high using either hot spot cell counting or visual estimation, further supporting the utility and reproducibility of these cost-efficient methods to assess proliferation. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 22, 2021 Category: Cancer & Oncology Source Type: research

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
ConclusionsSafety and efficacy with subcutaneous trastuzumab plus intravenous pertuzumab and docetaxel in mBC are consistent with historical evidence of intravenous trastuzumab with this combination. Findings further support subcutaneous administration not affecting safety/efficacy profiles of trastuzumab in HER2-positive BC with increased flexibility in patient care. A fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection has recently been approved for the treatment of HER2-positive early/mBC, further addressing the increasing relevance of and need for patient-centric treatment strategies.Trial r...
Source: Breast Cancer Research and Treatment - March 21, 2021 Category: Cancer & Oncology Source Type: research

Breast cancer treatment and survival differences in women in remote and socioeconomically disadvantaged areas, as demonstrated by linked data from New South Wales (NSW), Australia
ConclusionThis study provides benchmarks for monitoring future variations in treatment and survival. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 21, 2021 Category: Cancer & Oncology Source Type: research

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
ConclusionThe survival of patients with HER2  + ABC improved since the introduction of pertuzumab and T-DM1. There is room for improvement in implementation of these HER2-targeted therapies, especially in patients with HR + /HER2 + disease. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 20, 2021 Category: Cancer & Oncology Source Type: research

A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer
ConclusionsIn this propensity score-matched analysis of oncologic outcomes in breast cancer patients who underwent immediate reconstruction after NACT, no significant differences were observed between the IBBR and AFR groups. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 19, 2021 Category: Cancer & Oncology Source Type: research

Comparison of mastectomy and breast reconstruction outcomes using low thermal dissection versus traditional electrocautery: a blinded randomized trial
ConclusionUse of PlasmaBlade ® appears to be a safe and reliable technique to perform mastectomy and breast reconstruction with equivalent outcomes to traditional electrocautery. Although, mastectomy skin flap perfusion was rated better intra-operatively for the PlasmaBlade® group, both cohorts had comparable outcomes.ClinicalTrials.gov Identifier: NCT03711916Level of Evidence: I (Randomized trial). (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 19, 2021 Category: Cancer & Oncology Source Type: research

Every Day Counts: a randomized pilot lifestyle intervention for women with metastatic breast cancer
AbstractPurposeTo explore the feasibility, adherence, safety and potential efficacy ofEvery Day Counts; a randomized pilot trial designed for women with metastatic breast cancer (MBC) framed by the American Cancer Society nutrition and physical activity (PA) guidelinesMethodsWomen with clinically stable MBC were recruited to complete an interview, dual energy X-ray absorptiometry imaging and phlebotomy at baseline and post-intervention. Multidimensional quality of life, symptom burden, lifestyle behaviors (nutrition and PA) and biomarkers of prognosis were procured and quantified. Women were randomized to the immediate int...
Source: Breast Cancer Research and Treatment - March 19, 2021 Category: Cancer & Oncology Source Type: research

A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006)
ConclusionsPhysicians expressed interest in investigating a novel approach to breast cancer treatment that would omit surgery in complete responders to neoadjuvant chemotherapy. Multidisciplinary input, and specifically surgeon engagement, will be key to the success of future investigations. Ongoing work to develop approaches to predict pathologic complete response accurately is needed to achieve the promise of this idea.ClinTrials #: BR005: NCT03188393 June 13, 2017 (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 19, 2021 Category: Cancer & Oncology Source Type: research

Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study
ConclusionsNo association was observed between worry and uptake, although the relationship was affected by the categorisation of worry. Standardised reporting of the classification of worry is warranted to allow transparent comparisons across cohorts. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 17, 2021 Category: Cancer & Oncology Source Type: research

Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI
ConclusionSULpeak reduction rate of dbPET  >  82% was an independent indicator associated with pCR after NAC in breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 17, 2021 Category: Cancer & Oncology Source Type: research

Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies
ConclusionsThis study could help identify patients with ErbB2-positive tumors that are at increased risk of disease relapse following NATs. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 16, 2021 Category: Cancer & Oncology Source Type: research

Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES
ConclusionThe safety and efficacy results from EVEREXES trial are consistent to data previously reported in BOLERO-2. These results support that EVE  + EXE could be a viable treatment option for the postmenopausal women with HR+, HER2 − ABC in Asian region. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 16, 2021 Category: Cancer & Oncology Source Type: research

Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases
ConclusionPatients with axillary lymph node micrometastases showed a comparable outcome to node negative patients and their outcome was not significantly improved with CHT. Thus, axillary lymph node micrometastases should not be considered in the treatment decision. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 15, 2021 Category: Cancer & Oncology Source Type: research

Evaluation of online Spanish and English health materials for preventive mastectomy. are we providing adequate information?
ConclusionsOnline English and Spanish preventive mastectomy materials were written at an elevated reading level and lacked cultural sensitivity. Spanish language information demonstrated inferior understandability, actionability, and cultural sensitivity. Addressing these issues provides an opportunity to help resolve health literature disparities regarding preventive mastectomy for US Hispanic women. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 15, 2021 Category: Cancer & Oncology Source Type: research

Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands
ConclusionAn increasing number of Dutch breast cancer specialists is considering a repeat BCT feasible in selected cases, at the patient ’s preference and with partial breast re-irradiation. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 13, 2021 Category: Cancer & Oncology Source Type: research

Letter to the editor regarding: ‘Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire’
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 13, 2021 Category: Cancer & Oncology Source Type: research

Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial
ConclusionsThere is a relatively high risk of inadequate estrogen suppression in patients who switch from tamoxifen treatment to AIs. The use of sensitive and specific assays, such as LC –MS/MS methods, to monitor estrogen levels during AI treatment is essential to minimize the risk of a proceeding inefficient endocrine therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 12, 2021 Category: Cancer & Oncology Source Type: research

Shall patients ’ anxiety influence surgical decisions for atypical breast lesions? A substudy of the prospective NOMAT trial
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 12, 2021 Category: Cancer & Oncology Source Type: research

RE: Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early stage breast cancer patients
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 11, 2021 Category: Cancer & Oncology Source Type: research

Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer
ConclusionThe risk of 5-year LR as a first event was low and decreased with the number of event-free years. After three event-free years, the overall risk was 1%. This is reassuring to patients and also suggests that follow-up beyond 3 years may produce low yield of LR, both for individual patients and studies using LR as primary outcome. This can be used as a starting point to tailor follow-up to individual needs. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 10, 2021 Category: Cancer & Oncology Source Type: research

Characterization of estrogen receptor-low-positive breast cancer
ConclusionsPR status as a surrogate marker of functional ER signaling provides critical information in this regard. These findings suggest that while ER-low-positive tumors are themselves heterogeneous, they often respond to endocrine treatment. Analysis of molecular signatures and standardization of therapeutic strategies are important to understand the biology of ER-low-positive tumors and to enable optimal treatment in the pursuit of individualized medicine. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 10, 2021 Category: Cancer & Oncology Source Type: research

Variations in breast cancer surgical treatment and timing: determinants and disparities
AbstractPurposeTo describe clinical and non-clinical factors associated with receipt of breast conserving surgery (BCS) versus mastectomy and time to surgical intervention.MethodsCross-sectional retrospective study of January 1, 2012 through March 31, 2018 data from the IBM MarketScan Commercial Claims and Encounter and Medicare Supplemental Databases. Area Health Resource Files provided non-clinical characteristics and sociodemographic data. Eligibility: Female sex, claim(s) with ICD-9-CM or ICD-10-CM diagnosis of non-metastatic invasive breast cancer,  >  6 months of continuous insurance pre- and po...
Source: Breast Cancer Research and Treatment - March 10, 2021 Category: Cancer & Oncology Source Type: research

Long-term PM 2.5 exposure before diagnosis is associated with worse outcome in breast cancer
AbstractPurposeIncreasingly epidemiological evidence supports that environmental factors are associated with breast cancer (BC) outcomes after a BC diagnosis. Although evidence suggests that air pollution exposure is associated with higher mortality in women with BC, studies investigating potential mechanisms have been lacking.MethodsWe evaluated women with BC (N = 151) attended at the National Cancer Institute–Mexico from 2012 to 2015. We calculated 1-year average exposures to particulate matter 
Source: Breast Cancer Research and Treatment - March 8, 2021 Category: Cancer & Oncology Source Type: research

Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience
ConclusionOur study describes both the spectrum of cutaneous AE of palbociclib and endocrine therapy, and approaches to management. Prompt management may limit the negative impact on patients, facilitating beneficial continuation of palbociclib and endocrine therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 8, 2021 Category: Cancer & Oncology Source Type: research

Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women
ConclusionOur study observed that approximately half of the racial disparity between postmenopausal Black and White women in TNBC incidence was driven by metabolic dysfunction. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 7, 2021 Category: Cancer & Oncology Source Type: research